🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2028

Annual patent cliff calendar for 2028 — US pharmaceutical patents by expiration date.

Patents
603

Quick answer

603 indexed pharmaceutical patents have expiration dates in 2028. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 7351702

    Caspase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7351718

    Substituted pyrrolidine and related compounds

    Theravance, Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7351827

    Substituted oxetanes, method of making, and method of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7351707

    Spiroazacyclic compounds as monoamine receptor modulators

    ACADIA Pharmaceuticals Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7354900

    Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides

    The Board of Regents of the University of Oklahoma · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7354582

    Use of VEGF antagonists for the treatment of malignant gliomas

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7355079

    Thyronamine derivatives and analogs and methods of use thereof

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7355047

    Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7355012

    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7354909

    Method for rapid generation of mature dendritic cells

    UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7354939

    Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7354581

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7353829

    Methods and apparatus for multi-photon photo-activation of therapeutic agents

    Provectus Devicetech, Inc. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7354576

    Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7354578

    Method of tumor regression with VEGF inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7354579

    Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7354580

    Method of administering and using VEGF inhibitors for the treatment of human cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7354711

    Methods for inhibiting immunostimulatory DNA associated responses

    The Department of Veterans Affairs, as represented by the Secretary of United States of America · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7354761

    Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7354894

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7354912

    Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity

    The Board of Regents of the University of Texas System · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7354904

    Bacteriocin inducer peptides

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7354919

    Isoxazole compositions useful as inhibitors of ERK

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7354936

    2-phenylpyran-4-one derivatives

    ALMIRALL, LLC · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7355001

    Organic anion transport protein TCH229

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7354928

    Small molecule inhibitors targeted at Bcl-2

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7355078

    Processes for the preparation of tomoxetine

    Teva Pharmaceutical Fine Chemicals S.R.L. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7355018

    Modified IGF1 polypeptides with increased stability and potency

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7355046

    Biphenyl derivatives

    Theravance, Inc. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7358086

    Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

    The Regents of the University of California · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7357945

    Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7358085

    Anti-angiogenic methods and compositions

    Sangamo Biosciences, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7358247

    Mycophenolate mofetil impurity

    TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7358087

    Compositions and methods for enhancing immune responses mediated by antigen-presenting cells

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7358248

    Substituted amino carboxylic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7358390

    Polymorphic forms of nateglinide

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7358244

    Azabicycloalkane compounds

    Theravance, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7358259

    HCV inhibitors and methods of using them

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7358377

    Schweinfurthin analogues

    The United States of America · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7358260

    Quinuclidine derivatives and medicinal compositions containing the same

    Laboratories Almirall, S.A. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7358222

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7358258

    Prodrugs of an ERK protein kinase inhibitor

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7358364

    Substituted carboxylic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7358360

    Risedronate sodium having a very low content of iron

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7358273

    Inhibitors of caspases

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7358226

    Ultrasonic concentration of drug delivery capsules

    The Regents of the University of California · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7358229

    Deuterated cyclosporin analogs and their use as immunomodulating agents

    Isotechnika, Inc. · Granted Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7361332

    Treating tumors using implants comprising combinations of allogeneic cells

    The Regents of the University of California · Granted Tue Apr 22 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2028?

603 published patents in our USPTO index have expiration dates falling in calendar year 2028.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.